

Breaking Barriers: Mitigating Stigma to Control HIV Transmission

*Emmanuel Ifeanyi Obeagu¹, Getrude Uzoma Obeagu² and Amaeze Augustine Amaeze³

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

³Department of Physiotherapy, Evangel University, Akaeze, Ebonyi State, Nigeria.

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Human Immunodeficiency Virus (HIV) remains a significant global health concern, with stigma acting as a critical barrier to effective control and prevention. This review article delves into the complex interplay between stigma and HIV transmission, emphasizing the detrimental impact of societal attitudes on testing, treatment adherence, and healthcare access. Stigma perpetuates the cycle of transmission by fostering fear, discrimination, and reluctance to seek care, contributing to increased infection rates. Addressing stigma necessitates a comprehensive approach involving education, awareness campaigns, advocacy, and the creation of supportive environments. Efforts to mitigate stigma and discrimination not only enhance prevention strategies but also uphold the dignity and rights of individuals affected by HIV. This review advocates for a concerted global effort to break down barriers, combat stigma, and create inclusive systems that promote equitable access to healthcare and support services for all affected populations.

Keywords: *HIV, stigma, transmission, public health, awareness, education, discrimination, healthcare, social attitudes, prevention, advocacy*

Introduction

Human Immunodeficiency Virus (HIV) remains a persistent global health challenge, affecting millions of lives and posing significant social, economic, and health implications worldwide.

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

Despite remarkable advancements in medical science, the stigma and discrimination surrounding HIV continue to impede effective control measures and hinder progress toward curbing transmission rates. Stigma, deeply rooted in societal attitudes and misconceptions about HIV, acts as a formidable barrier, creating obstacles at every stage of prevention, diagnosis, and treatment.¹⁻¹⁰ The impact of stigma on HIV transmission extends far beyond individual experiences; it reverberates throughout communities and entire societies. Stigmatizing attitudes not only discourage individuals from seeking testing and treatment but also perpetuate myths and misconceptions, leading to a climate of fear, discrimination, and exclusion. These factors not only undermine public health initiatives but also fuel the spread of the virus by impeding access to essential care and fostering behaviors that increase transmission risks.¹¹⁻²⁰

This paper aims to delve deeply into the intricate relationship between stigma and HIV transmission, emphasizing the urgent need for concerted efforts to mitigate stigma as a crucial step toward controlling the epidemic. By exploring the multifaceted repercussions of stigma on healthcare access, prevention strategies, and societal perceptions, this review will underscore the critical importance of addressing stigma as a fundamental component of comprehensive HIV control efforts. Efforts to mitigate stigma surrounding HIV require a holistic approach encompassing education, community engagement, policy reforms, and healthcare system improvements.²¹ By examining the impact of stigma on various facets of HIV transmission and control, this article advocates for the implementation of inclusive and stigma-free environments that prioritize access to equitable healthcare services and support for all individuals affected by HIV.

Stigma's Impact on HIV Transmission

Stigma surrounding HIV/AIDS significantly influences the transmission dynamics of the virus, creating formidable barriers at various stages of prevention, diagnosis, and treatment.²² Stigma attached to HIV leads to fear, shame, and discrimination, discouraging individuals from seeking testing or disclosing their status. As a result, many people delay getting tested or avoid it altogether. Late diagnosis not only hampers timely interventions but also increases the risk of unintentional transmission due to unawareness of one's HIV-positive status.²³⁻²⁸ Stigma contributes to poor treatment adherence among those living with HIV. Fear of discrimination or social isolation often leads individuals to conceal their status or forego treatment, impacting their ability to adhere to medication regimens. Inadequate adherence increases viral loads, raising the risk of transmission to others.²⁹⁻³³ Stigma fosters an environment where open discussions about safe sex practices and risk reduction become challenging. Individuals may avoid seeking information or assistance related to safe sex or harm reduction due to societal judgment, leading to increased transmission risks through unprotected sex or sharing contaminated needles among certain populations.

Stigma disproportionately affects marginalized groups such as sex workers, LGBTQ+ communities, and people who inject drugs. These populations face intersecting stigmas based on their HIV status, gender identity, sexual orientation, or occupation, amplifying their vulnerability to HIV transmission due to social exclusion and limited access to healthcare.³⁴ Stigma exacerbates

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

psychological distress and social isolation among individuals living with HIV. Discriminatory attitudes can lead to depression, anxiety, and low self-esteem, affecting mental health outcomes and reducing one's ability to engage in preventive behaviors or access necessary support services.³⁵⁻³⁹ Stigma impedes effective public health interventions by hindering open dialogue, community engagement, and the implementation of evidence-based strategies. In areas where stigma is pervasive, outreach efforts, education campaigns, and initiatives promoting testing and prevention may face resistance or reluctance to participate.

Healthcare Disparities and Stigma

Healthcare disparities stemming from stigma associated with HIV/AIDS pose significant challenges in ensuring equitable access to quality healthcare services. Stigmatizing attitudes and discriminatory practices within healthcare settings discourage individuals from seeking HIV-related care. Fear of judgment, breaches of confidentiality, or past experiences of discrimination lead to reluctance in accessing healthcare services, resulting in delayed or forgone treatment.⁴⁰⁻⁴⁵ Stigma contributes to unequal treatment experiences for individuals living with HIV. Those facing stigma may receive substandard care, encounter disrespectful treatment from healthcare providers, or experience neglect, affecting treatment adherence and overall health outcomes.⁴⁶⁻⁵¹ Marginalized populations, including racial and ethnic minorities, LGBTQ+ individuals, sex workers, and people who inject drugs, face amplified healthcare disparities due to intersecting stigmas. Systemic discrimination and biases hinder their access to competent and culturally sensitive care, exacerbating disparities in HIV prevention, testing, and treatment.³⁴

Stigma intersects with geographic and socioeconomic disparities, limiting access to healthcare resources. Rural communities or economically disadvantaged areas may lack adequate HIV-related services, exacerbating barriers to care for individuals in these regions. Stigma creates an environment where individuals fear disclosing their HIV status to healthcare providers due to concerns about confidentiality breaches or discriminatory treatment. This fear erodes trust between patients and healthcare systems, further deterring individuals from seeking necessary care and support. Community engagement and empowerment, alongside advocacy for policies that protect the rights of individuals living with HIV, are crucial in addressing healthcare disparities. Creating supportive environments that foster trust, encourage disclosure, and ensure access to comprehensive care for all individuals affected by HIV is essential in reducing disparities and improving health outcomes. Efforts to mitigate stigma within healthcare settings are pivotal in achieving equitable access to healthcare services and enhancing the overall well-being of those impacted by HIV.⁵²⁻⁵⁸

Mitigating Stigma: Strategies for Control and Prevention

Mitigating stigma associated with HIV/AIDS demands a multifaceted approach encompassing various strategies aimed at control, prevention, and societal change. Promoting accurate information about HIV transmission, prevention, and treatment through comprehensive educational campaigns is crucial. These initiatives debunk myths, challenge misconceptions, and

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

cultivate understanding to reduce fear and discrimination associated with HIV.⁵⁹⁻⁶⁴ Engaging communities affected by HIV in dialogue, decision-making processes, and support networks fosters empowerment. Community-led initiatives play a pivotal role in advocating for the rights of affected individuals, fostering solidarity, and reducing isolation. Collaboration with media outlets to portray accurate and non-stigmatizing representations of HIV/AIDS is essential. Responsible reporting and positive portrayal of individuals living with HIV help reshape societal perceptions and reduce negative stereotypes.⁶⁵⁻⁷⁰

Training healthcare providers in culturally competent care, empathy, and non-discriminatory practices is imperative. Implementing policies that safeguard patient confidentiality and protect against discrimination within healthcare settings is essential to promote trust and accessibility. Advocating for legal protections and policies that safeguard the rights of individuals living with HIV is crucial. Anti-discrimination laws and policies that promote equality in employment, housing, healthcare, and education contribute significantly to reducing stigma.⁷¹⁻⁷⁹ Establishing peer support networks and counseling services provides emotional support, fosters resilience, and assists in addressing the psychosocial impact of stigma on individuals living with HIV. Encouraging the use of language that is inclusive, respectful, and devoid of judgment is essential in reducing stigma. Employing person-centered language that emphasizes the individual over their HIV status helps in humanizing the narrative. Integrating HIV education into school curricula fosters understanding, reduces discrimination, and promotes supportive environments for affected individuals, contributing to shaping more accepting attitudes among younger generations. Collaboration between governmental and non-governmental organizations, healthcare providers, community-based groups, and affected individuals is vital in implementing comprehensive strategies to combat stigma effectively. Mitigating stigma surrounding HIV/AIDS is an ongoing process that requires sustained efforts at individual, community, and societal levels. These strategies, when implemented collectively, contribute to creating a more compassionate, supportive, and inclusive environment for individuals affected by HIV, ultimately contributing to effective HIV control and prevention.

The Role of Advocacy and Supportive Environments

Advocacy and the creation of supportive environments play pivotal roles in mitigating stigma associated with HIV/AIDS. Advocacy efforts empower affected communities to assert their rights, challenge discriminatory practices, and demand inclusive policies. These initiatives amplify the voices of those impacted by HIV, advocating for their needs and promoting social justice.⁸⁰ Advocacy plays a crucial role in influencing policymakers to create and implement policies that protect the rights of individuals living with HIV. This includes advocating for anti-discrimination laws, access to healthcare, and supportive services.⁸¹ Advocacy efforts challenge stigmatizing legislation or policies that perpetuate discrimination against individuals based on their HIV status, sexual orientation, gender identity, or other factors. These initiatives aim to promote laws that protect against discrimination and uphold human rights.⁸²

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

Advocacy campaigns contribute to raising awareness about the realities of HIV/AIDS, dispelling myths, and addressing misconceptions. They help to reshape societal attitudes, reduce fear, and promote empathy and understanding. Creating supportive environments involves establishing spaces where individuals affected by HIV feel safe, respected, and supported. This includes healthcare settings, workplaces, educational institutions, and communities that prioritize inclusivity, confidentiality, and non-discrimination. Advocacy efforts often involve training and capacity-building programs for various stakeholders, including healthcare professionals, policymakers, community leaders, and the general public. These programs aim to equip individuals with the knowledge and skills to address stigma effectively.⁸¹

Collaboration between advocacy groups, governmental organizations, healthcare providers, academia, and affected communities fosters synergy in addressing stigma. By working together, these partnerships strengthen advocacy initiatives, share resources, and maximize impact. Advocacy seeks to ensure diverse representation of affected populations in decision-making processes, ensuring that policies and interventions are inclusive and sensitive to the unique needs of various communities. Advocacy efforts often involve establishing support networks and counseling services that offer emotional support, guidance, and resources to individuals affected by HIV, reducing isolation and promoting well-being. Advocacy efforts alongside the creation of supportive environments are essential in challenging stigma, promoting inclusivity, and advocating for the rights and well-being of individuals living with HIV. These initiatives contribute significantly to building more compassionate and understanding societies, fostering resilience, and ultimately reducing the impact of stigma on HIV/AIDS transmission and control.⁸²

Conclusion

The persistent stigma surrounding HIV/AIDS continues to impede progress in controlling the epidemic, posing significant challenges at individual, societal, and global levels. Throughout this review, the multifaceted impact of stigma on HIV transmission and control has been explored, highlighting its detrimental effects on healthcare access, prevention strategies, and the well-being of affected populations. Stigma acts as a formidable barrier, hindering individuals from seeking testing, disclosing their status, adhering to treatment, and accessing necessary healthcare services. This reluctance perpetuates the cycle of transmission, fostering fear, discrimination, and social isolation among those affected. Marginalized populations face amplified stigmatization, exacerbating healthcare disparities and increasing vulnerability to HIV transmission.

Combating stigma associated with HIV/AIDS is integral to effective control and prevention strategies. It requires sustained efforts across various sectors, emphasizing education, advocacy, policy reforms, and the creation of supportive environments. Breaking barriers and mitigating stigma not only enhance HIV control measures but also uphold the dignity, rights, and well-being of all individuals affected by HIV.

References

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-8. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-9.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpe M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-9.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. Elite Journal of HIV, 2024; 2(2): 30-42

13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6.
https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5.
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-9.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf).
18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.
https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf.
20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJCRRAR.pdf)
21. Mahajan AP, Sayles JN, Patel VA, Remien RH, Sawires SR, Ortiz DJ, Szekeres G, Coates TJ. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. Aids. 2008;22: S67-79.

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. Elite Journal of HIV, 2024; 2(2): 30-42

22. Hood JE, Friedman AL. Unveiling the hidden epidemic: a review of stigma associated with sexually transmissible infections. *Sexual health*. 2011;8(2):159-70.
23. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
24. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports*. 2023;6(8):e1450.
25. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005).
26. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):128-34. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
27. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022:29-34.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeke M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
29. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005).
30. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-42.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
31. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-34.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
32. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.*

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

- 2017;3(5):100-4.DOI: [10.22192/ijcrms.2017.03.05.014](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
[https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfected with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf)
33. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
 34. Baral S, Holland CE, Shannon K, Logie C, Semugoma P, Sithole B, Papworth E, Drame F, Beyrer C. Enhancing benefits or increasing harms: community responses for HIV among men who have sex with men, transgender women, female sex workers, and people who inject drugs. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2014;66: S319-28.
 35. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences*. 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
 36. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-83.DOI: [DOI: 10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137)
[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137)
 37. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
 38. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-11. <http://research.sdpublishers.net/id/eprint/2819/>.
 39. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
 40. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-8.
 41. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

- HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
42. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
 43. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
 44. Nwosu DC, Nwanjo HU, Okolie NJ, Ikech K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatananya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160.
[links/5a4fd0500f7e9bbbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjps.in/links/5a4fd0500f7e9bbbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
 45. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-9.
 46. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcreps.2019.06.12.004
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.in/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
 47. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.in/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
 48. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.in/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
 49. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-10.
https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
 50. Obeagu EI, Okeke EI, Anode Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
 51. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRS). 2023;3(2):28-31.

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. Elite Journal of HIV, 2024; 2(2): 30-42

52. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-7.
53. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-9.
54. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
55. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-30.
56. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-9.
57. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
58. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-1.
59. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-71.
60. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickel Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
61. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-8.
62. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-6.
63. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
64. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-5.

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. Elite Journal of HIV, 2024; 2(2): 30-42

65. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-9.
66. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
67. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
68. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
69. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
70. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
71. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
- 72.
73. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
- 74.
75. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
- 76.
77. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res*. 2023;10(10):56-62.

Citation: Obeagu EI, Obeagu GU, Amaeze AA. Breaking Barriers: Mitigating Stigma to Control HIV Transmission. *Elite Journal of HIV*, 2024; 2(2): 30-42

78. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
79. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
80. Johnson L. Culturally responsive leadership for community empowerment. Multicultural education in glocal perspectives: Policy and institutionalization. 2017:183-99.
81. World Health Organization. HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers. World Health Organization; 2013.
82. Blake VK, Hatzenbuehler ML. Legal remedies to address stigma-based health inequalities in the United States: challenges and opportunities. The Milbank Quarterly. 2019;97(2):480-504.